139264-17-8
139264-17-8
Chemical Structure
Zolmitriptan
Synonym(s): BW-311C90; 311C90
- CAS No.: 139264-17-8
- Formula:C16H21N3O2
- Molecular Weight:287.36
IUPAC Name: (S)-4-((3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)methyl)oxazolidin-2-one
InChIKey: ULSDMUVEXKOYBU-ZDUSSCGKSA-N
SMILES: O=C1OC[C@H](CC2=CC3=C(NC=C3CCN(C)C)C=C2)N1
Biological Activity: Zolmitriptan (BW-311C90; 311C90) is a 5-HT1B/1D receptor partial agonist that can cross the blood-brain barrier, with Kis of 5.01 nM, 0.63 nM, and 63.09 nM for 5-HT1B, 5-HT1D, 5-HT1F receptor, respectively. Zolmitriptan can be used for the research of migraine[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Zolmitriptan | 99.95% | Zolmitriptan (BW-311C90; 311C90) is a 5-HT1B/1D receptor partial agonist that can cross the blood-brain barrier, with Kis of 5.01 nM, 0.63 nM, and 63.09 nM for 5-HT1B, 5-HT1D, 5-HT1F receptor, respectively. Zolmitriptan can be used for the research of migraine. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Zolmitriptan-d6 | Zolmitriptan-d6 is deuterium labeled Zolmitriptan. Zolmitriptan (BW-311C90; 311C90) is a 5-HT1B/1D receptor partial agonist with Kis of 5.01 nM, 0.63 nM, and 63.09 nM for 5-HT1B, 5-HT1D, 5-HT1F receptor, respectively. Zolmitriptan can be used for the research of migraine. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. G R Martin, et al. Receptor specificity and trigemino-vascular inhibitory actions of a novel 5-HT1B/1D receptor partial agonist, 311C90 (zolmitriptan). Br J Pharmacol. 1997 May;121(2):157-64. [Content Brief]
- [2]. Katherine C Murray, et al. Polysynaptic excitatory postsynaptic potentials that trigger spasms after spinal cord injury in rats are inhibited by 5-HT1B and 5-HT1F receptors. J Neurophysiol. 2011 Aug;106(2):925-43. [Content Brief]
- [3]. MacLennan SJ, et al. Cranial vascular effects of zolmitriptan, a centrally active 5-HT1B/1D receptor partial agonist for the acute treatment of migraine. Eur J Pharmacol. 1998 Nov 20;361(2-3):191-7. [Content Brief]
